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Abstract
IMPORTANCE—Cancer is among the leading causes of death worldwide. Current estimates of 
cancer burden in individual countries and regions are necessary to inform local cancer control 
strategies.
OBJECTIVE—To estimate mortality, incidence, years lived with disability (YLDs), years of life 
lost (YLLs), and disability-adjusted life-years (DALYs) for 28 cancers in 188 countries by sex 
from 1990 to 2013.
EVIDENCE REVIEW—The general methodology of the Global Burden of Disease (GBD) 2013 
study was used. Cancer registries were the source for cancer incidence data as well as mortality 
incidence (MI) ratios. Sources for cause of death data include vital registration system data, verbal 
autopsy studies, and other sources. The MI ratios were used to transform incidence data to 
mortality estimates and cause of death estimates to incidence estimates. Cancer prevalence was 
estimated using MI ratios as surrogates for survival data; YLDs were calculated by multiplying 
prevalence estimates with disability weights, which were derived from population-based surveys; 
YLLs were computed by multiplying the number of estimated cancer deaths at each age with a 
reference life expectancy; and DALYs were calculated as the sum of YLDs and YLLs.
FINDINGS—In 2013 there were 14.9 million incident cancer cases, 8.2 million deaths, and 196.3 
million DALYs. Prostate cancer was the leading cause for cancer incidence (1.4 million) for men 
and breast cancer for women (1.8 million). Tracheal, bronchus, and lung (TBL) cancer was the 
leading cause for cancer death in men and women, with 1.6 million deaths. For men, TBL cancer 
was the leading cause of DALYs (24.9 million). For women, breast cancer was the leading cause 
of DALYs (13.1 million). Age-standardized incidence rates (ASIRs) per 100 000 and age-
standardized death rates (ASDRs) per 100 000 for both sexes in 2013 were higher in developing 
vs developed countries for stomach cancer (ASIR, 17 vs 14; ASDR, 15 vs 11), liver cancer (ASIR, 
15 vs 7; ASDR, 16 vs 7), esophageal cancer (ASIR, 9 vs 4; ASDR, 9 vs 4), cervical cancer (ASIR, 
8 vs 5; ASDR, 4 vs 2), lip and oral cavity cancer (ASIR, 7 vs 6; ASDR, 2 vs 2), and 
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nasopharyngeal cancer (ASIR, 1.5 vs 0.4; ASDR, 1.2 vs 0.3). Between 1990 and 2013, ASIRs for 
all cancers combined (except nonmelanoma skin cancer and Kaposi sarcoma) increased by more 
than 10% in 113 countries and decreased by more than 10% in 12 of 188 countries.
CONCLUSIONS AND RELEVANCE—Cancer poses a major threat to public health 
worldwide, and incidence rates have increased in most countries since 1990. The trend is a 
particular threat to developing nations with health systems that are ill-equipped to deal with 
complex and expensive cancer treatments. The annual update on the Global Burden of Cancer will 
provide all stakeholders with timely estimates to guide policy efforts in cancer prevention, 
screening, treatment, and palliation.
Cancer caused over 8 million deaths worldwide in 2013 and has moved from the third 
leading cause of death in 1990 to the second leading cause behind cardiovascular disease in 
2013.1-3 Substantial progress has been made in recent years with regard to prevention and 
treatment options for certain cancers.4-6 However, despite this progress, cancer burden is 
increasing owing to a growing and aging global population as well as risk factors like 
smoking, obesity, and dietary patterns. To appropriately allocate resources to prevention, 
screening, diagnosis, treatment, and palliative care and to monitor their effectiveness, it is 
necessary to have timely information about cancer burden for individual countries. The 
Global Burden of Disease (GBD) study provides a comprehensive assessment of incidence, 
mortality, and disability for all major diseases and injuries. Herein, we present detailed 
results of the GBD 2013 study1 for 28 cancer groups covering cancer incidence, mortality, 
and disability for 188 countries from 1990 to 2013 for both sexes and different age groups.
A Video summary of this article is available on the JAMA Oncology website.
Methods
The general methods that have been used in the GBD study have been published 
previously.1,2,7-14 The present study specifically explains the methodological components 
pertaining to cancer estimation for GBD 2013. Box 1 includes a list of the figures and tables 
in this article. Further details about methods and data sources are provided in the eAppendix, 
eFigures, and eTables in the Supplement, and Box 2 contains a list of the supplementary 
figures and tables. Additional information is available from the authors in web tables 1 
through 9, which are available at the web addresses listed in Box 3. Hereinafter, citations to 
web tables are for those given in Box 3.
The analytical strategy can be broken into 7 components, as shown in eFigure 1 in the 
Supplement. The first step involved extraction of mortality and incidence data from data 
sources collected for the GBD study. Data on cancer incidence and cancer mortality were 
sought from individual cancer registries, literature reviews, and the Cancer Incidence in Five 
Continents (CI5) series.15-24 Only data representative of the registries’ catchment area and 
including all cancer sites for both sexes were used. The most recent data available for any 
source until 2012 were incorporated. eTable 1 in the Supplement lists cancer registry data 
used by country. Just over half (53%) of cancer incidence data were reported in CI5, 
whereas 47% came from cancer registries from other sources. Data were extracted at the 
most detailed cause- and age-specific level. International Classification of Diseases, Ninth 
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Revision (ICD-9) and International Classification of Diseases, Tenth Revision (ICD-10) 
codes for each GBD cancer group as well as steps explaining data preparation can be found 
in the eAppendix in the Supplement. Twentyeight cancer groups were defined that include 
all ICD codes pertaining to neoplasms (ICD-9, 140-239; ICD-10, C00-D49) except for 
Kaposi sarcoma (KS) (C46) and nonmelanoma skin cancer (NMSC) (C44). eTable 3 in the 
Supplement lists the ICD-9 and ICD-10 codes included in each cancer group.
In the second step, mortality incidence(MI) ratios (cancer deaths divided by cancer incident 
cases) were estimated for each cancer site, country, age, sex, and year.
In the third step, the MI ratios were applied to cancer incidence data to transform incidence 
data to mortality estimates. Mortality data from cancer registries were only used to generate 
MI ratios and did not contribute to the cancer mortality estimates to avoid counting the 
cancer registry data twice. eTable 1 in the Supplement lists which cancer registry data were 
used for MI ratio estimation. The incidence-based mortality estimates became part of the 
GBD CoD (cause of death) database. The methods used to generate the CoD database are 
reported in detail elsewhere.1 In brief, all published and unpublished data relevant to 
estimating causes of death for 188 countries from 1980 to 2013 were identified. The sources 
include vital registration systems, verbal autopsy studies, and other sources (eTable 2 in the 
Supplement). Cancer registry data contributed 37% to the cancer-specific data in the CoD 
database; the other sources contributed 63%.
In the fourth step, the CoD database mortality data (including the cancer incidence data 
transformed to mortality estimates through the use of MI ratios) were used as input into the 
Cause of Death Ensemble Model (CODEm) to estimate the number of deaths attributable to 
each cancer assessed in the analysis.25 The CODEm results were adjusted using CoDcorrect, 
an algorithm that uses uncertainty distributions around cause fraction estimates for each 
GBD cause of death to scale estimates to all-cause mortality estimates in each country, year, 
age, and sex group. These death estimates were used to calculate years of life lost (YLLs).
The fifth step was to apply MI ratios to CoDcorrect death estimates to obtain cancer 
incidence estimates for each country, year, age, and sex group.
In the sixth step, MI ratios were transformed into an access-to-care variable to scale 
countries between a theoretical best-case and worst-case survival to generate relative 
survival curves. The relative survival was then adjusted for background mortality using 
GBD life-tables, and absolute survival rates were estimated.
In step 7, the absolute survival estimates were used to generate 10-year cancer prevalence 
estimates. Total prevalence was subdivided into general cancer sequelae like (1) diagnosis 
and treatment, (2) metastatic phase, and (3) terminal phase for the estimated deaths. After 
these 3 sequelae were assigned, the remaining prevalent time was considered remission. 
Prevalence for cancer-specific sequelae for breast cancer (mastectomy), larynx cancer 
(laryngectomy), colon and rectum cancer (stoma), bladder cancer (incontinence), and 
prostate cancer (impotence and incontinence) was also estimated. To calculate years lived 
with disability (YLDs), each sequela was multiplied with specific disability weights, which 
were derived from population-based surveys.11,26 Disability-adjusted life-years (DALYs), 
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which combine health loss with premature mortality, were calculated by using the sum of 
YLLs and YLDs.
This analysis does not provide estimates for NMSC or KS because NMSC is an exceptional 
cancer with a very high incidence, which is usually not collected by cancer registries, and 
low mortality, and KS is attributed to human immunodeficiency virus in the GBD 
framework.
Results
Global Incidence, Mortality, and DALYs
In 2013, there were 14.9 million incident cancer cases world wide and 8.2 million cancer 
deaths as detailed in Table 1. Cancer caused 196.3 million DALYs in 2013 (web table 9); 
56% of incident cases, 62% of deaths, and 70% of DALYs occurred in developing countries. 
eFigure 5 in the Supplement shows that between 1990 and 2013, the proportion of deaths 
from noncommunicable diseases (NCDs) substantially increased (from 57% in 1990 to 70% 
in 2013), with a decrease in deaths due to communicable, maternal, neonatal, and nutritional 
diseases (from 34% in 1990 to 22% in 2013). The proportion of cancer deaths as part of all 
deaths has increased from 12% in 1990 to 15% in 2013. Between 1990 and 2013, absolute 
DALYs due to all cancers (excluding NMSC and KS) for both sexes increased by 29% 
globally, by 10% in developed countries, and by 40% in developing countries. Age-
standardized DALYs decreased by 20% globally, by 21% in developed countries, and by 
18% in developing countries (web table 9).
Men were more likely to develop cancer between birth and age 79 years, with 1 in 3 men 
and 1 in 5 women developing cancer worldwide, as detailed in eTable 17 in the Supplement. 
In 2013, the cancers with the highest incidence on a global scale for men were prostate 
cancer (1.4 million), tracheal, bronchus, and lung (TBL) cancer (1.3 million), and colon and 
rectum cancer (873 000), as detailed in Table 1. The top 3 causes of cancer death and 
DALYs for men were TBL cancer (1.2 million deaths, 24.9 million DALYs), liver cancer 
(564 000 deaths, 15.2 million DALYs), and stomach cancer (530 000 deaths, 11.7 million 
DALYs) (Table 1; web table 6). For women, the cancers with the highest incidence were 
breast cancer (1.8 million), colon and rectum cancer (700 000), and TBL cancer (535 000). 
The top 3 causes of cancer death for women were TBL cancer (485 000), breast cancer (464 
000), and colon and rectum cancer (357 000) (Table 1). In 2013, the top 3 causes for 
DALYs in women were breast cancer (13.1 million), TBL cancer (9.8 million), and cervical 
cancer (6.9 million) (web table 3).
The contribution of different cancers to total incidence and death by age group is shown in 
Figure 1. Brain and nervous system cancer, Hodgkin lymphoma, non-Hodgkin lymphoma 
(NHL), leukemia, and the combined “other cancer” group (a group containing rare cancers 
like malignant neoplasm of bone and articular cartilage of limbs, malignant neoplasm of 
thymus, and others—see eTable 15 in the Supplement for a full list of ICD codes) are the 
main contributors to cancer incidence in children and adolescents (age<20 years). Brain and 
nervous system cancer, NHL, leukemia, and cancers from the other cancer group cause most 
of the cancer deaths in this young age group. In young and middle-aged adults breast, 
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cervical, colon and rectum cancer, brain and nervous system cancer, and cancers from the 
other cancer group add the largest fraction to total incidence. Stomach, liver, TBL, and 
breast cancer contribute the most to cancer deaths. For older adults (>54 years) stomach, 
TBL, breast, prostate, and colon and rectum cancers are the biggest contributors to 
incidence. Stomach, liver, TBL, and colon and rectum cancer cause the majority of cancer 
deaths in older adults.
For all cancers combined (excluding NMSC and KS), ASIRs between 1990 and 2013 
increased in 153 of 188 countries (Figure 2A), with many countries in parts of Northern 
Africa and the Middle East, sub-Saharan Africa, Southeast Asia, and Oceania having 
experienced increases of over 20%. However, ASDRs for all cancers combined (excluding 
NMSC and KS) decreased within that timeframe in 126 of 188 countries (Figure 2B).
Top 10 Cancers (Ranked by the Highest Number of Incident Cases Globally in 2013)
Tracheal, Bronchus, and Lung Cancer—In 2013, there were an estimated 1.8 million 
incident cases of TBL cancer and 1.6 million deaths. Tracheal, bronchus, and lung cancer 
caused 34.7 million DALYs in 2013, with 62% occurring in developing countries and 38% 
occurring in developed countries (web table 9). Men were more likely to develop lung 
cancer than women, with 1 in 18 men and 1 in 51 women being diagnosed between birth and 
age 79 years. Tracheal, bronchus, and lung cancer has the second highest absolute incidence 
globally as well as in developing countries and ranks fourth in developed countries (Figure 
3). It was the most common cause of cancer death by absolute cases globally as well as in 
developing and developed regions (Figure 4).
As detailed in web tables 4 and 5, ASIRs per 100 000 for men were the lowest in western 
sub-Saharan Africa (with ASDRs per 100 000 reported for comparison) (ASIR, 6.33; 
ASDR, 6.36), eastern sub-Saharan Africa (ASIR, 8.01; ASDR, 8.52), and central sub-
Saharan Africa (ASIR, 12.77; ASDR, 13.08) and the highest in central Europe (ASIR, 
66.10; ASDR, 63.87), east Asia (ASIR, 64.68; ASDR, 60.13), and high-income North 
America (ASIR, 61.5; ASDR, 51.02).
For women in 2013, incidence rates per 100 000 were the lowest in western sub-Saharan 
Africa (with death rates per 100 000 reported for comparison) (ASIR, 2.76; ASDR, 2.96) 
followed by eastern sub-Saharan Africa (ASIR, 3.15; ASDR, 3.51), and south Asia (ASIR, 
3.80; ASDR, 4.12) and the highest in high-income North America (ASIR, 41.83; ASDR, 
31.33), Australasia (ASIR, 25.23; ASDR, 20.46), and east Asia (ASIR, 22.88; ASDR, 22.16) 
(web tables 1 and 2).
eFigure 6a and c in the Supplement shows that TBL cancer was the cancer with the most 
incident cases for men in 40 countries, with a predominance in central and eastern Europe, 
Asia, and northern Africa, and TBL was the most common cause for cancer death in 103 
countries. For women, TBL cancer was the most common cause of cancer death in Albania, 
Andorra, Australia, Brunei, Canada, China, Cuba, Denmark, United Kingdom, Hungary, 
Ireland, Iceland, Cambodia, South Korea, Laos, Myanmar, Netherlands, New Zealand, 
Poland, North Korea, Singapore, Timor-Leste, Taiwan, and the United States (eFigure 6d in 
the Supplement).
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Between 1990 and 2013, TBL cancer remained the leading cause of cancer YLLs (Figure 5). 
A decrease in incidence rates between 1990 and 2013 with stable population size and age 
structure would have resulted in a 13% decrease in incident cases (Table 2). However, 
overall incident cases increased by 62% because of population growth and aging. The 
ASIRs per 100 000 for both sexes between 1990 and 2013 decreased by 6% at the global 
level (31.12 to 29.36), by 14% for developed countries (43.81 to 37.74) but increased by 9% 
in developing countries (23.04 to 25.18) (web table 7).
At the global level, incidence for women has risen slowly, whereas rates have fallen for men 
since the mid-1990s (Figure 6). The same trends can be seen in developed regions. 
However, in developing regions, rates are still increasing for men. Age-standardized DALY 
rates for both sexes between 1990 and 2013 have decreased by 17% at the global level, by 
23% for developed countries, and by 7% for developing countries (web table 9).
Breast Cancer—Since only 1% of breast cancer cases in 2013 occurred in men, only 
female breast cancer is discussed herein. In 2013, there were 1.8 million incident cases of 
breast cancer and 464 thousand deaths. Breast cancer caused 13.1 million DALYs in 2013 
(web table 3), with 63% occurring in developing countries and 37% occurring in developed 
countries. One in 18 women developed breast cancer between birth and age 79 years.
As detailed in web tables 1 and 2, in 2013, ASIRs per 100 000 were the lowest in western 
sub-Saharan Africa (with ASDRs per 100 000 reported for comparison) (ASIR, 28.24; 
ASDR, 10.65), east Asia (ASIR, 33.52; ASDR, 6.87), and eastern sub-Saharan Africa 
(ASIR, 33.67; ASDR, 13.71) and the highest in Oceania (ASIR, 133.38; ASDR, 28.89), 
high-income North America (ASIR, 111.01; ASDR, 19.07), and Australasia (ASIR, 91.12; 
ASDR, 19.63).
Breast cancer was the cancer with the highest incidence for women in 161 countries 
(eFigure 6b in the Supplement) and the most common cause for cancer deaths in women in 
98 countries (eFigure 6d in the Supplement).
Figure 5 shows that breast cancer ranked sixth in 1990 for cancer YLLs, but it moved to 
fifth place in 2013. Compared with 1990, in 2013, incident cases increased by 898 000 (99% 
increase). With stable population size and age structure, breast cancer incidence would have 
increased by 26% due to increasing incidence rates. Population aging with unchanged 
incidence rates or population growth would have led to a 38% increase in incidence (Table 
2).
Globally, female breast cancer incidence has been continuously increasing, with a slower 
increase since 2000 (Figure 7). Even though female breast cancer incidence is lower in 
developing countries, it is increasing rapidly compared with developed countries, where 
rates have been stable to declining since the early 2000s. Between 1990 and 2013, ASIRs 
per 100 000 have increased by 17% globally (44.36 to 51.73), by 46% in developing 
countries (27.74 to 40.40) and by 8% in developed countries (69.75 to 74.98) (web table 1). 
Age-standardized DALY rates have decreased by 17% at the global level, by 25% for 
developed countries, and by 3% for developing countries (web table 3).
Page 6
JAMA Oncol. Author manuscript; available in PMC 2015 July 14.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Colon and Rectum Cancer—In 2013, there were 1.6 million incident cases of colon and 
rectum cancer, and it caused 771 000 deaths. Colon and rectum cancer caused 15.8 million 
DALY sin 2013, with 56% occurring in developing countries and 44% occurring in 
developed countries (web table 9). The probability of developing colon and rectum cancer 
before age 79 years was higher for men than for women (1 in 27 men; 1 in 43 women).
Globally, colon and rectum cancer ranked third for cancer incidence and fourth for cancer 
death in 2013 (Figures 3 and 4). For developed countries it ranked second for incidence and 
mortality, and in developing countries it ranked fourth for both incidence and mortality.
As detailed in in web tables 4 and 5, the 2013 incidence rates per 100 000 for men were the 
lowest in western sub-Saharan Africa (with ASDRs per 100 000 reported for comparison) 
(ASIR, 9.12; ASDR, 6.51), south Asia (ASIR, 10.26; ASDR, 6.07), and eastern sub-Saharan 
Africa (ASIR, 12.73; ASDR, 9.91) and the highest in Australasia (ASIR, 60.64; ASDR, 
22.29), high-income Asia Pacific (ASIR, 58.48; ASDR, 22.56), and western Europe (ASIR, 
55.69; ASDR, 24.24). For women, incidence rates per 100 000 in 2013 were the lowest in 
south Asia (with ASDRs per 100 000 reported for comparison) (ASIR, 6.04; ASDR, 3.98), 
western sub-Saharan Africa (ASIR, 6.95; ASDR,5.49), and eastern sub-Saharan Africa 
(ASIR, 9.86; ASDR, 8.57) and the highest in Australasia (ASIR, 43.75; ASDR, 15.95), 
high-income North America (ASIR, 39.95; ASDR, 13.12), and western Europe (ASIR, 
33.96; ASDR, 15.01) (web tables 1 and 2). eFigure 6a and cin the Supplement show that 
colon and rectum cancer was the cancer with the highest incidence in 2013 for men in 
Bulgaria, Brunei, Hungary, Japan, Kuwait, Saudi Arabia, Singapore, Slovakia, and Taiwan 
and the most common cause of cancer death in Ethiopia and Tanzania. For women, colon 
and rectum cancer was the cancer with the highest incidence in Japan and the most common 
cause of death in Spain, Japan, Norway, Portugal, and Sweden (eFigure 6b and d in the 
Supplement).
Figure 5 shows that colon and rectum cancer remained the fourth leading cause for cancer 
YLLs between 1990 and 2013. Table 2 details how in 2013 almost twice as many people 
were diagnosed with colon and rectum cancer as in 1990 (818 000 in 1990, 1.6 million in 
2013). Most of this increase can be explained by an aging and growing population, but even 
with the same population size and structure, colon and rectum cancer cases would have 
increased by 16% between 1990 and 2013 due to an increase in incidence rates.
Figure 8 shows that worldwide ASIR for colon and rectum cancer for women between 1990 
and 2013 remained stable but increased for men. As detailed in web tables 1 and 4, ASIRs 
increased by 1% between 1990 and 2013 for women and by 16% for men. In developed 
countries, ASIRs decreased by 3% in women and increased by 8% in men. However, in 
developing regions, rates have risen rapidly, with a 53% increase in men and a 31% increase 
in women between 1990 and 2013. Between 1990 and 2013, age-standardized DALY rates 
for both sexes have decreased by 15% at the global level, by 18% in developed countries, 
and by 2% in developing countries (web table 9).
Prostate Cancer—In 2013, there were 1.4 million incident cases of prostate cancer and 
293 000 deaths. Prostate cancer caused 4.8 million DALYs globally in 2013, with 57% 
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occurring in developed countries, and 43% occurring in developing countries (web table 9). 
The probability of developing prostate cancer is detailed in eTable 17 in the Supplement, 
with 1 in 15 men developing prostate cancer between birth and age 79 years.
Our web tables 4 and 5 detail how incidence rates per 100 000 in 2013 were the lowest in 
south Asia (with ASDRs per 100 000 reported for comparison) (ASIR, 9.9; ASDR, 2.39), 
east Asia (ASIR, 13.99; ASDR, 3.43), and central Asia (ASIR, 25.57; ASDR, 7.91) and the 
highest in high-income North America (ASIR, 184.23; ASDR, 19.7), the Caribbean (ASIR, 
154.97; ASDR, 49.05), and Australasia (ASIR, 144.81; ASDR, 26.53).
eFigure 6a and c in the Supplement shows that in 2013, prostate cancer was the cancer with 
the highest incidence for men in 104 of 188 countries, and the leading cause of cancer death 
for men in 24 countries.
Prostate cancer ranked 15th for cancer YLLs in 1990 and 13th in 2013 as can be seen in 
Figure 5. Table 2 details how the increasing incidence together with an aging and growing 
population have led to a more than 3-fold increase in prostate cancer cases since 1990 (454 
000 in 1990, 1.4 million in 2013). The ASIR for prostate cancer had the steepest increase 
between 1990 and 2013 of all cancers in men (Figure 9). As listed in web table 4, ASIRs per 
100 000 increased by 69% globally (32.42 to 54.68), by 135% in developing countries 
(13.29 to 31.25), and by 63% in developed countries (61.51 to 100.29). Prostate cancer 
incidence rates are still lower in developing countries than in developed countries, but 
because of a faster increase in rates in developing countries, the gap decreased between 1990 
and 2013 from a 4-fold to a 3-fold difference. During the same timeframe, age-standardized 
DALY rates have decreased by 3% at the global level and by 9% in developed countries but 
have increased by 28% in developing countries (web table 9).
Stomach Cancer—In 2013, there were 984 000 incident cases of stomach cancer and 841 
000 deaths. Stomach cancer caused 17.9 million DALYs in 2013, with 77% occurring in 
developing countries, and 23% occurring in developed countries (web table 9). One in 36 
men and 1 in 84 women developed stomach cancer before age 79 years. Globally, stomach 
cancer ranked fifth for cancer incidence and second for cancer deaths in 2013 (Figures 3 and 
4). For developed countries, it ranked fifth for incidence and third for mortality, and in 
developing countries, it ranked third for both incidence and mortality.
The ASIRs and ASDRs per 100 000 in 2013 for both sexes were higher in developing 
countries vs developed countries (ASIR, 16.9 vs 14.38; ASDR, 15.33 vs 11.07) (web tables 
7 and 8). As detailed in web tables 4 and 5, the 2013 incidence rates per 100 000 for men 
were the lowest in southern sub-Saharan Africa (with ASDRs per 100 000 reported for 
comparison) (ASIR, 8.27; ASDR, 6.97), south Asia (ASIR, 9.01; ASDR, 9.19), and eastern 
sub-Saharan Africa (ASIR, 9.12; ASDR, 10.01) and the highest in high-income Asia Pacific 
(ASIR, 42.31; ASDR, 31.61), east Asia (ASIR, 39.16; ASDR, 34.12), and Andean Latin 
America (ASIR, 32.61; ASDR, 27.96). For women, incidence rates per 100 000 in 2013 
were the lowest in southern sub-Saharan Africa (with ASDRs per 100 000 reported for 
comparison) (ASIR, 4.54; ASDR, 3.93), high-income North America (ASIR, 4.65; ASDR, 
2.94), and Australasia (ASIR, 5.37; ASDR, 3.84) and the highest in Andean Latin America 
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(ASIR, 24.62; ASDR, 21.69), high-income Asia Pacific (ASIR, 20.00; ASDR, 14.86), and 
east Asia (ASIR, 14.78; ASDR, 13.37) (web tables 1 and 2).
Stomach cancer was the cancer with the highest absolute incidence in 2013 for men in 
Honduras, Iran, Kyrgyzstan, and Tajikistan and the leading cause of cancer death in Bolivia, 
Central African Republic, Chile, Democratic Republic of the Congo, Congo, Colombia, 
Cape Verde, Costa Rica, Ecuador, Guatemala, Honduras, Iran, Kyrgyzstan, Oman, Peru, El 
Salvador, and Tajikistan (eFigure 6a and c in the Supplement). For women, it was the cancer 
with the most incident cases in Cape Verde and the leading cause of cancer death in 
Afghanistan, Bolivia, Cape Verde, Ecuador, Guatemala, Honduras, Peru, Tajikistan, and 
Vietnam (eFigure 6b and d in the Supplement).
Stomach cancer decreased from the second highest cause for crude cancer YLLs in 1990 to 
the third highest in 2013, with a 2.5% decrease in absolute YLLs due to cancer (Figure 5). If 
the population age structure and size had remained the same in 2013 as it was in 1990, 
incidence would have dropped by 52.2% due to decreasing rates (Table 2). As illustrated in 
Figure 10, ASIRs have dropped substantially since 1990, Between 1990 and 2013 age-
standardized DALYs for both sexes decreased by 42% globally, by 49% in developed 
countries, and by 40% in developing countries (web table 9).
Liver Cancer—In 2013, there were 792 000 incident cases of liver cancer globally and 818 
000 deaths. Liver cancer caused 20.9 million DALYs in 2013, with 86% occurring in 
developing countries and 14% occurring in developed countries (web table 9). Liver cancer 
is more common in men, with 1 in 45 men being diagnosed before age 79 years compared 
with 1 in 121 women. Globally, liver cancer ranked sixth for cancer incidence and third for 
cancer death in 2013 as shown in Figures 3 and 4. For developed countries it ranked 11th for 
incidence and seventh for mortality, and in developing countries it ranked fifth for incidence 
and second for mortality.
The ASIRs and ASDRs for liver cancer per 100 000 in 2013 for both sexes were higher in 
developing countries vs developed countries (ASIR, 14.72 vs 7.42; ASDR, 15.59 vs 7.26) 
(web tables 7 and 8). As web tables 4 and 5 detail, in 2013 incidence rates per 100 000 for 
men were the lowest in tropical Latin America (with ASDRs per 100 000 reported for 
comparison) (ASIR, 5.86; ASDR, 6.45), eastern Europe (ASIR, 6.07; ASDR, 6.46), and 
Australasia (ASIR, 6.26; ASDR,5.69) and the highest in east Asia (ASIR, 36.66; ASDR, 
36.88), western sub-Saharan Africa (ASIR, 30.53; ASDR, 33.68), and high-income Asia 
Pacific (ASIR, 30.16; ASDR, 29.48). For women incidence rates in 2013 per 100 000 were 
the lowest in eastern Europe (ASIR, 2.52; ASDR, 2.85), Australasia (ASIR, 2.72; ASDR, 
2.68), and high-income North America (ASIR, 2.87; ASDR, 2.72) and the highest in western 
sub-Saharan Africa (ASIR, 13.17; ASDR, 14.79), east Asia (ASIR, 11.89; ASDR, 13.09), 
and Oceania (ASIR, 10.01; ASDR, 11.18) (web tables 1 and 2).
Liver cancer was the most commonly diagnosed cancer in 2013 for men in Benin, Burkina 
Faso, Cameroon, Guinea, The Gambia, Guinea-Bissau, Liberia, Mali, Mongolia, Mauritania, 
Niger, Senegal, Sierra Leone, Chad, Togo, Thailand, and Vietnam (eFigure 6a in the 
Supplement) and the most common cause of cancer death in Burundi, Benin, Burkina Faso, 
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Bangladesh, Côte d’Ivoire, Cameroon, Egypt, Eritrea, Fiji, Ghana, Guinea, The Gambia, 
Guinea-Bissau, Liberia, Madagascar, Mali, Mongolia, Mauritania, Niger, Nigeria, Rwanda, 
Saudi Arabia, Senegal, Sierra Leone, Chad, Togo, Thailand, Taiwan, and Vietnam (eFigure 
6c in the Supplement).
For women in 2013, liver cancer was the most commonly diagnosed cancer as well as the 
leading cause of cancer death in Mongolia (eFigure 6b and d in the Supplement).
Figure 3 shows a marked difference between the 50 most populous countries for liver cancer 
incidence rankings. For example, while it ranks in most of these countries among the top 10 
cancers for incidence, it ranks 21st in Ukraine, 19th in Poland, and 18th in the United States, 
the United Kingdom, Argentina, and Canada.
Liver cancer has increased from the third leading cause for cancer YLLs in 1990 to the 
second leading cause in 2013 (Figure 5). Aging and population growth are the drivers of the 
increase from 465 000 cases in 1990 to 792 000 cases in 2013 (Table 2). If the population 
age structure and size had remained the same in 2013 as they were in 1990, 1.8% fewer 
cases of liver cancer would have been diagnosed in 2013 than in 1990. Worldwide, as well 
as in developing regions, ASIRs appear to have peaked in the late 1990s, with a slow 
decrease in rates since 2000 (Figure 11). Between 1990 and 2013, age-standardized DALY 
rates for both sexes for liver cancer decreased by 14% at the global level, by 20% in 
developing countries, and by 4% in developed countries (web table 9).
Cervical Cancer—In 2013, 485 000 women were diagnosed with cervical cancer 
worldwide, and it caused 236 000 deaths. Cervical cancer caused 6.9 million DALYs, with 
85% occurring in developed countries and 15% occurring in developing countries. One in 70 
women developed cervical cancer between birth and age 79 years.
The ASIRs and ASDRs per 100 000 in 2013 were higher in developing countries vs 
developed countries (ASIR, 15.70 vs 9.58; ASDR, 8.32 vs 3.96) (web tables 1 and 2). In 
2013, incidence rates per 100 000 were the lowest in Australasia (with ASDRs per 100 000 
reported for comparison) (ASIR, 6.83; ASDR, 2.65), north Africa and Middle East (ASIR, 
7.23; ASDR, 3.19) and high-income North America (ASIR, 7.26; ASDR, 2.84), and the 
highest in Oceania (ASIR, 58.4; ASDR, 26.49), eastern sub-Saharan Africa (ASIR, 31.5; 
ASDR, 25.57), and western sub-Saharan Africa (ASIR, 30.2; ASDR, 22.3).
Cervical cancer was the most commonly diagnosed cancer in 2013 for women in 
Afghanistan, Benin, Central African Republic, Cameroon, Eritrea, Ghana, Guinea, The 
Gambia, Guinea-Bissau, Guatemala, Liberia, Lesotho, Mali, Mauritania, Malawi, Niger, 
Nigeria, Nicaragua, Senegal, Sierra Leone, El Salvador, Somalia, Chad, Togo, Uganda, 
Zambia, and Zimbabwe (eFigure 6b in the Supplement) and the most common cause of 
cancer death for women in Angola, Burundi, Benin, Burkina Faso, Central African 
Republic, Côte d’Ivoire, Cameroon, Democratic Republic of the Congo, Congo, Comoros, 
Djibouti, Eritrea, Ethiopia, Ghana, Guinea, Guinea-Bissau, Equatorial Guinea, Indonesia, 
Kenya, Liberia, Lesotho, Madagascar, Mali, Mozambique, Mauritania, Malawi, Niger, 
Nigeria, Nicaragua, Papua New Guinea, Paraguay, Rwanda, Senegal, Sierra Leone, El 
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Salvador, Somalia, South Sudan, Sao Tome and Principe, Swaziland, Chad, Togo, Tanzania, 
Uganda, Zambia, and Zimbabwe (eFigure 6d in the Supplement).
Cervical cancer was the eighth leading cause for cancer YLLs in 1990 and the ninth leading 
cause in 2013, with a 32% decrease in age-standardized YLLs (Figure 5). Total incidence 
would have decreased by 59% if the population size and age structure had remained the 
same in 2013 as it was in 1990 due to decreasing incidence rates (Table 2). Both globally 
and in developing regions, ASIRs for cervical cancer have decreased (Figure 12). Between 
1990 and 2013, age-standardized DALYs decreased globally by 32%, in developing 
countries by 36%, and in developed countries by 34% (web table 3).
Non-Hodgkin Lymphoma—In 2013, there were 465 000 incident cases of NHL and 226 
000 deaths. Non-Hodgkin lymphoma caused 6.4 million DALYs in 2013, with 71% 
occurring in developing countries and 29% occurring in developed countries (web table 9). 
One in 103 men and 1 in 151 women developed NHL cancer between birth and age 79 
years.
Globally, NHL ranked eighth for cancer incidence and 11th for cancer death in 2013 
(Figures 3 and 4). For developed countries, it ranked seventh for incidence and ninth for 
mortality, and in developing countries it ranked 11th for both incidence and mortality.
As detailed in web tables 4 and 5, 2013 NHL incidence and rates per 100 000 for men were 
the lowest in Oceania (with ASDRs per 100 000 reported for comparison) (ASIR, 3.13; 
ASDR, 1.80), western sub-Saharan Africa (ASIR, 4.10; ASDR, 3.50), and central Asia 
(ASIR, 4.52; ASDR, 3.04) and the highest in high-income North America (ASIR, 22.09; 
ASDR, 7.74), Australasia (ASIR, 15.43; ASDR, 7.49), and western Europe (ASIR, 14.19; 
ASDR, 6.04).
For women, NHL incidence rates per 100 000 in 2013 were the lowest in central Asia 
(ASIR, 2.35; ASDR, 1.32), western sub-Saharan Africa (ASIR, 2.68; ASDR, 1.96), and 
south Asia (ASIR, 3.27; ASDR, 2.37) and the highest in high-income North America (ASIR, 
15.01; ASDR, 4.79), Australasia (ASIR, 10.74; ASDR, 4.71), and Western Europe (ASIR, 
9.56; ASDR, 3.66) (web tables 1 and 2). Non-Hodgkin lymphoma was the most commonly 
diagnosed cancer in 2013 for men in the United Arab Emirates and Qatar (eFigure 6a in the 
Supplement).
Non-Hodgkin lymphoma ranked 10th for cancer YLLs in 1990 and 11th in 2013 (Figure 5). 
More than twice as many cases of NHL were diagnosed in 2013 as in 1990 (465 000 vs 227 
000). Population growth alone would have increased incidence by 35%; population aging 
alone would have increased incidence by 30%; and an increase in incidence rates assuming 
stable population age structure and size between 1990 and 2013 would have led to a 41% 
increase in new cases (Table 2). Figure 13 illustrates the slight increase in ASIRs between 
1990 and 2013. On the global level, ASIRs per 100 000 for both sexes for NHL increased by 
26% (5.8 to 7.3), with a larger increase in developing countries (44%, 3.6 to 5.2) than in 
developed countries (23%, 9.2 to 11.3) (web table 7).
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During this timeframe, age-standardized DALY rates for both sexes decreased by 3% at the 
global level, by 8% in developing countries, and increased by 2% in developing countries 
(web table 9).
Esophageal Cancer—In 2013 there were 442 000 new cases of esophageal cancer and 
440 000 deaths. Esophageal cancer caused 9.8 million DALYs in 2013, with 84% occurring 
in developing countries and 16% occurring in developed countries (web table 9). Men had a 
higher probability than women for developing esophageal cancer between birth and age 79 
years, with 1 in 73 men being diagnosed vs 1 in 203 women.
Globally, esophageal cancer ranked ninth for cancer incidence and sixth for cancer death in 
2013 (Figures 3 and 4). In developed countries, esophageal cancer was only the 20th 
greatest cause for cancer incidence but the 11th leading cause for cancer death. In 
developing countries, esophageal cancer ranked eighth for cancer incidence and fifth for 
mortality.
Esophageal cancer ASIRs and ASDRs per 100 000 in 2013 for both sexes were higher in 
developing countries vs developed countries (ASIR, 8.94 vs 3.90; ASDR, 9.11 vs 3.79) (web 
tables 7 and 8). As detailed in web tables 4 and 5, in 2013 incidence rates per 100 000 for 
men were the lowest in Andean Latin America (ASIR, 2.41; ASDR, 2.49), central Latin 
America (ASIR, 3.46; ASDR, 3.51), and north Africa and Middle East (ASIR, 3.46; ASDR, 
3.74) and the highest in east Asia (ASIR, 22.04; ASDR, 22.4), southern sub-Saharan Africa 
(ASIR, 21.81; ASDR, 22.33), and central Asia (ASIR, 14.42; ASDR, 14.55). For women, 
incidence rates per 100 000 in 2013 were the lowest in Andean Latin America (with ASDRs 
per 100 000 reported for comparison) (ASIR, 0.64; ASDR, 0.64), eastern Europe (ASIR, 
0.88; ASDR, 0.92), and central Europe (ASIR, 0.99 ASDR, 1.02) and the highest in eastern 
sub-Saharan Africa (ASIR, 12.74; ASDR, 13.78), southern sub-Saharan Africa (ASIR, 8.79; 
ASDR, 8.55), and south Asia (ASIR, 7.28; ASDR, 7.44) (web tables 1 and 2).
Esophageal cancer was the most commonly diagnosed cancer in 2013 for men in Malawi 
and Turkmenistan (eFigure 6a in the Supplement) and the most common cause of cancer 
death in Comoros, Djibouti, Kenya, Malawi, Somalia, South Sudan, Turkmenistan, and 
Zimbabwe (eFigure 6c in the Supplement). For women, it was the most common cause of 
cancer death in 2013 in Iran and Turkmenistan (eFigure 6d in the Supplement).
Figure 3 shows a marked difference between the 50 most populous countries for esophageal 
cancer incidence rankings in 2013. For example, while this cancer ranked in most countries 
among the least common cancers for incidence, it was the second most common cancer for 
both sexes in Kenya, and the fourth most common cancer in Iran. The same holds true for 
cancer death rates, where esophageal cancer ranks first in Kenya and Nepal, second in 
Ethiopia, Iran, South Africa, and Uganda, but only 16th in the Philippines and 17th in Peru.
Esophageal cancer has increased from the seventh leading cause for cancer YLLs in 1990 to 
the sixth leading cause in 2013 (Figure 5). Aging and growing populations are the drivers 
behind the increase in esophageal cancer cases from 304 000 in 1990 to 442 000 in 2013. If 
the population age structure and size had remained the same in 2013 as in 1990, 29.3% 
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fewer cases of esophageal cancer would have been diagnosed in 2013 than in 1990 (Table 
2). Worldwide and in developing regions, age-standardized incidence rates appear to be 
declining (Figure 14). Between 1990 and 2013, age-standardized DALY rates for both sexes 
decreased by 23% globally, by 28% in developing countries, and by 18% in developed 
countries (web table 9).
Leukemia—In 2013, there were 414 000 new cases of leukemia worldwide and 265 000 
deaths. Leukemia caused 9.3 million DALYs globally, with 78% occurring in developing 
countries and 22% occurring in developed countries (web table 9). One in 127 men vs 1 in 
203 women developed leukemia between birth and age 79 years.
Globally, leukemia ranked 10th for cancer incidence and ninth for cancer deaths in 2013. In 
developed countries, leukemia ranked 12th for incidence and eighth for cancer deaths. In 
developing countries, it ranked 10th for cancer incidence and eighth for cancer deaths 
(Figures 3 and 4).
The ASIRs and ASDRs per 100 000 in 2013 for both sexes were higher in developed 
countries vs developing countries (ASIR, 8.15 vs 5.09; ASDR, 4.78 vs 3.46) (web tables 7 
and 8). In 2013 incidence rates per 100 000 for both sexes were the lowest in western sub-
Saharan Africa (with ASDRs per 100 000 reported for comparison) (ASIR, 1.34; ASDR, 
1.15), eastern sub-Saharan Africa (ASIR, 1.58; ASDR, 1.47), and central sub-Saharan 
Africa (ASIR, 2.30; ASDR, 2.03) and highest in high-income North America (ASIR, 10.67; 
ASDR, 5.54), Australasia (ASIR, 9.97; ASDR, 5.13), and Western Europe (ASIR, 8.24; 
ASDR, 5.08).
Leukemia was the cancer with the most incident cases in 2013 for men in Iraq (eFigure 6a in 
the Supplement).
eFigure 4a in the Supplement shows a marked difference in incidence rankings between 
countries. Leukemia ranks among the top most common cancers for both sexes in Iraq, 
Jordan, and Kuwait, while it is much less common in most other countries. Leukemia has 
decreased from the fifth leading cause of cancer YLLs in 1990 to the seventh leading cause 
in 2013, with a 9% decrease in absolute YLLs and a 31% decrease in age-standardized 
YLLs (Figure 5).
Between 1990 and 2013, incident cases at the global level increased from 297 000 to 414 
000, with population growth and aging being the drivers behind this increase. Had ASIRs 
remained the same in 2013 as in 1990, there would be 8% more cases of leukemia in 2013 
(Table 2). For women, trends in ASIRs appear to be decreasing globally as well as in 
developed and developing countries (Figure 15). For men, ASIRs increased up to the 
mid-1990s and have decreased since in developing countries, with a stable trend in 
developing countries.
Between 1990 and 2013, age-standardized DALY rates for both sexes decreased by 30% at 
the global level, by 33% in developed countries, and by 30% in developing countries (web 
table 9).
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Trends in Incidence for Less Common Cancers
As detailed in web table 7, ASIRs per 100 000 for both sexes increased substantially 
between 1990 and 2013 for certain cancers. Kidney cancer ASIRs, for example, increased 
for both sexes by 23% (from 3.82 to 4.7). Rates in developing countries were lower than in 
developed countries but the relative increase was similar: 34% increase in developing 
countries (from 1.69 to 2.27) and 36% increase in developed countries (from 7.15 to 9.71).
For thyroid cancer, ASIRs per 100 000 on a global scale for both sexes increased by 20% 
(from 2.74 to 3.3), with a larger relative increase in developing countries (33%; from 2.06 to 
2.74) than in developed countries (19%; from 4.16 to 4.95).
Mesothelioma ASIRs per 100 000 increased by 15% for both sexes globally (from 0.48 to 
0.55), with a larger relative increase in developing countries of 26% (from 0.31 to 0.39) 
compared with a 14% increase in developed countries (from 0.7 to 0.8).
Pancreatic cancer ASIRs per 100 000 have increased globally for both sexes by 9% (5.31 to 
5.78) with a larger relative increase in developing (29% from 2.84 to 3.66) compared with 
developed countries (10% from 8.6 to 9.54).
For other cancers, rates substantially decreased between 1990 and 2013. Globally, ASIRs 
per 100 000 for both sexes for gallbladder and biliary tract cancer decreased by 23% (from 
3.99 to 3.09), with a smaller relative decrease of 18% in developing countries (from 3.09 to 
2.52) compared with a 25% decrease in developed countries (from 5.1 to 3.81). eFigure 4a 
in the Supplement shows that gallbladder and biliary tract cancer is exceptionally common 
in Chile, Bolivia, and South Korea, where it ranks sixth and seventh for cancer incident 
cases vs most other countries, where it is much less common. Specific ASIRs per 100 000 
confirm this finding: 14.85 in Bolivia, 11.54 in South Korea, and 16.03 in Chile (web table 
7). Larynx cancer ASIRs per 100 000 for both sexes decreased globally by 25% (from 3.7 to 
2.78), with a smaller decrease of 14% in developing countries (from 3.22 to 2.76) compared 
with a 37% decrease in developed countries (4.62 to 2.92).
On a global scale, nasopharynx cancer ASIRs per 100 000 decreased for both sexes by 25% 
(from 1.64 to 1.23), with a smaller decrease of 27% in developing countries (from 2.07 to 
1.52) compared with a 46% decrease in developed countries (from 0.79 to 0.43).
Hodgkin lymphoma ASIRs per 100 000 for both sexes decreased globally by 34% (from 
2.02 to 1.33), with a larger 37% decrease in developing countries (from 1.9 to 1.2) compared 
with a 19% decrease in developed countries (from 2.31 to 1.87).
Discussion
Descriptive cancer epidemiology has a long tradition and has influenced research and policy 
alike. Trends in cancer incidence are especially informative from both a health systems and 
a scientific perspective. They can help with resource allocation planning as a window into 
the future, and they can be hypothesis generating with regard to the driving factors behind 
changes. The GBD provides a unique source for data on cancer for 3 reasons: (1) a 
standardized statistical framework has been used to analyze both cancer registry data and 
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cause of death data by country and over time; (2) in addition to incidence and mortality, 
other metrics such as DALYs have been used to quantify health loss; and (3) the burden 
caused by an individual disease can be placed in the context of other diseases or injuries, 
which is sine qua non to inform health policy and resource allocation decisions.
The estimates presented in this study reveal remarkable differences in trends between 
cancers. On a global level between 1990 and 2013, incident cases for every cancer increased 
(increases ranging from 9% for cervical cancer to 217% for prostate cancer) except for 
Hodgkin lymphoma, for which incidence has decreased by 10% (from 103 000 to 93 000). 
Since the risk for most cancers increases with age, it is not surprising that aging contributed 
between 20% and 43% to the absolute increase in incident cases between 1990 and 2013 
(Table 2). With life expectancy increasing globally, the future burden of cancer will likely 
increase, unless incidence rates fall substantially.1 An example of such dramatically 
decreasing incidence rates from the present study is cervical cancer; incidence rates in this 
disease decreased by 59% between 1990 and 2013, which led to only a 8.5% increase in 
incident cases. In contrast, the increase in incident cervical cancer cases would have been 
67% if incidence rates had remained constant. Additional examples of countervailing trends 
include cancers more common in younger age groups like Hodgkin lymphoma, leukemia, 
testicular cancer, and brain and nervous system cancer, where population aging does not 
contribute to an increase in incident cases.
Of special concern are the increasing incidence rates in cancers that are also more common 
in older age groups, since this combination leads to the largest increase in incident cases. 
Prostate cancer, NHL, thyroid cancer, breast cancer, mesothelioma, colon and rectum 
cancer, and pancreatic cancer all fall into this category. Prostate cancer cases increased by 
217% between 1990 and 2013 on a global scale, by 169% in developed countries, and by 
361% in developing countries. Population aging has contributed a larger proportion to this 
increase in developing countries vs developed countries (54% vs 39%) (eTable 16 in the 
Supplement), which is not surprising, given the faster rise in life expectancy in developing 
countries. However, 265% of the 361% increase in incidence numbers is due to an increase 
in age-specific incidence rates. It is unclear how much of the overall increase can be 
attributed to ascertainment bias, but it is unlikely that this would fully explain such a 
substantial increase in developing countries, given that screening for prostate cancer is not 
widely practiced in low- and middle-income countries.
Between 1990 and 2013, kidney cancer cases for both sexes increased by 107%, with equal 
contribution from aging populations and increasing incidence rates. Incidence rates are still 
over 4-fold lower in developing countries than in developed countries but with a surprisingly 
similar relative increase in ASIRs (34% in developing countries, 36% in developed 
countries). This is an exception to most other cancers for which relative changes in trends 
show a marked difference by development status. Many potential risk factors for kidney 
cancer have been described in the literature, including smoking, obesity, hypertension, and 
occupational exposures.27-30 One possible explanation for the similar trend in incidence 
rates between developing and developed countries is that even though single risk factors for 
kidney cancer differ by development status, the overall risk factor pattern might compensate 
for this disparity.
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Thyroid cancer is another example of a cancer with an alarming rise in incidence. For both 
sexes, incident cases almost doubled between 1990 and 2013 (95% increase). Population 
growth, aging, and increasing rates contributed similar proportions to this increase. 
However, while ASIRs increased globally by 20%, ASDRs decreased by 19% (web table 8). 
This finding supports the previously recognized notion that at least part of the “thyroid 
cancer epidemic” can be attributed to overdiagnosis due to the increased use of imaging 
examinations.31-33
In contrast to the group of cancers where rising incidence rates contribute substantially to 
the increase in absolute cases are the group of cancers with decreasing rates. Population 
growth and aging still result in a larger number of cases in 2013 compared with 1990, but 
part of this increase is offset by falling rates. At the global level, Hodgkin lymphoma and 
cervical, stomach, larynx, nasopharynx, gallbladder and biliary tract, esophageal, and 
bladder cancer fall into this group.
Focusing on Cancer Prevention
Obviously the interpretation of trends simplifies substantial differences between and within 
regions and countries as well as between age groups. The estimates are therefore also 
provided at the country level, by age and sex groups. However, the description of patterns 
by development status or region can help correct misconceptions. Cancer has long been 
regarded as a problem of economically developed countries, with the reasoning that cancer 
burden is substantially higher in affluent countries and that cancer care requires too many 
resources and is too complex to provide in less developed countries. The lack of focus on 
cancer and other NCDs is highlighted by the Millennium Development Goals (MDGs),34 
which do not include any NCDs. However, eventhough the total 2013 ASIR per 100 000 for 
cancer was 1.7 times higher in developed regions vs developing regions (328 vs 190), death 
rates per 100 000 were only 1.2 times higher (148 vs 123). Between 1990 and 2013, ASIRs 
increased in most countries (Figure 2A), including developing countries, where the existing 
health care systems are already overwhelmed by the burden of communicable diseases. This 
rise in cancer incidence has been attributed to increased life expectancy and an increasing 
prevalence of risk factors like overweight and obesity, smoking, alcohol consumption, and 
hypertension.1,35-37 To avoid an NCD epidemic that could reverse health care advances 
already achieved in reducing the burden of communicable disease, cancer prevention efforts 
must be a priority.
Tracheal, bronchus, and lung cancer, cervical cancer, and liver cancer are good examples in 
this aspect. Currently, TBL cancer ASIRs for men in regions with low smoking prevalence 
like sub-Saharan Africa (except southern sub-Saharan Africa) are 5 to 10 times lower than in 
countries with historically high smoking prevalence like high-income North America, 
Europe, and east Asia. For women, the difference is even more striking, with a 15-fold 
difference in 2013 ASIRs per 100 000 between western sub-Saharan Africa and high-
income North America (2.76 vs 41.8), and it is critical that public health efforts ensure that 
smoking rates remain low in the future.38,39 However, smoking is only 1 risk factor for TBL 
cancer. East Asian women have the third highest ASIR for TBL cancer (23 per 100 000), 
behind high-income North America (42 per 100 000) and Australasia (25 per 100 000), even 
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though smoking rates are substantially lower for women in east Asia than they are in other 
countries with similar incidence rates.38 Genetic susceptibility might play a role, but 
preventable risk factors like household air pollution have also been identified as a reason 
behind this unusual pattern.40-44
Cervical cancer rates in regions with screening programs, like Australasia, high-income 
North-America, Western Europe, and high-income Asia Pacific, are below 10 per 100 000, 
whereas rates are up to 3 times as high in countries without screening programs (29 per 100 
000 in Andean Latin America, 30 per 100 000 in western sub-Saharan Africa, and 58 per 
100 000 in Oceania). It is encouraging that between 1990 and 2013, cervical cancer ASIRs 
decreased in all regions between 8% and 47% (web table 1). However, in 2013, cervical 
cancer, a preventable and treatable cancer, remains the cancer with the highest incidence in 
women in 27 countries and the leading cause of cancer death in women in 45 countries. 
Efforts to determine the most cost-effective strategies to reduce cervical cancer burden 
through human papillomavirus vaccination and screening are ongoing and will hopefully 
lead to a continued decrease in cervical cancer incidence in the most affected areas of the 
world.45-50
Liver cancer ranks second for mortality in developing countries. Treatment for liver cancer 
is not very effective, with 2013 ASIRs and ASDRs per 100 000 being very similar in both 
developing and developed countries (ASIRs, 14.72 and 7.42, respectively; ASDRs, 15.59 
and 7.26, respectively). The main risk factors for liver cancer are hepatitis B infection, 
hepatitis C infection, and chronic hepatitis and cirrhosis due to alcohol and other 
causes.51-56 In 2013, of the 818 000 deaths in men and women, 300 000 (37%) were 
estimated to be due to hepatitis B infection, 343 000 (42%) due to hepatitis C infection, 92 
000 (11%) due to alcohol abuse, and 83 000 (10%) due to other causes.1 Hepatitis B 
vaccination has proven cost-effective in preventing liver cancer due to hepatitis B, and 
treatment for hepatitis C, although expensive, has recently shown success.57,58
Study Limitations
The core components of the GBD cancer estimates are cancer registry and vital registry data. 
However, these sources are sparse in many low-and middle-income countries, and in the 
absence of data, the estimates are dependent on covariate selection and regional patterns. 
This is accounted for by estimating uncertainty intervals (provided for all estimates in 
eTables in the Supplement). Even though cancer registry data are considered the gold 
standard for cancer surveillance, the quality of registries can vary substantially. 
Underreporting of cancer cases or deaths or a high proportion of undefined codes can lead to 
cancer registry data that do not represent the true cancer burden.59-62 As described in the 
Methods section, our analysis is therefore heavily based on cause-of-death data and to a 
lesser degree on cancer registry data. This explains why the estimates reported might be 
different from cancer registry data. To ensure consistency, robustness, and clarity in this 
framework, the same estimation methods were used for all cancers, as well as advanced 
modeling techniques like ensemble models with a large pool of covariates and out-of-sample 
validation. The benefit of estimating the different cancers within the GBD framework is that 
it ensures that cancer estimates are adjusted to be consistent with the all-cause mortality 
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estimates, preventing inflation or underestimation of cause-specific estimates. A detailed 
description of these methods is provided in the eAppendix in the Supplement. While quite 
advanced, these methodologies still result in only estimates, which should be used as 
placeholders until high-quality data become available. Hopefully, the newly launched 
Global Initiative for Cancer Registry Development,63 an effort to expand cancer registries in 
low- and middle-income countries, will lead to improved data availability and quality in 
these countries.
Underreporting of new cancer cases to cancer registries or miscoding cause of death can 
lead to MI ratios that are either too low or too high.64,65 Miscoding is especially common in 
countries with limited diagnostic resources and arises when metastatic lesions are coded as 
primary cancers, which can lead to overestimation of primary cancers in anatomic sites 
where metastases are often found (eg, liver or brain). Also, increasing incidence rates with 
stable mortality rates can lead to an underestimation of MI ratios, and decreasing incidence 
rates with stable mortality rates can lead to MI ratios higher than 1. These factors can result 
in seemingly implausible estimates like higher estimates for cancer deaths compared with 
cancer incident cases in the same year. Changing classification systems (eg, from ICD-9 
Basic Tabulation List to ICD-9 detail) can also lead to substantial changes in estimates over 
time. To improve the quality of the data sources and to ensure comparability, garbage codes 
or undefined cancer codes were redistributed, and different coding systems were mapped to 
a set of uniform GBD causes.
To estimate YLDs, MI ratios were used as surrogates for cancer survival owing to lack of 
high-quality survival data in most countries. Using MI ratios as a surrogate for survival is 
problematic because of the different patient cohorts with changing survival probabilities that 
are captured in the mortality numerator. The approach taken in the present analysis, 
therefore, was to use MI ratios as a surrogate for access to care, which avoids the problem 
with “back-scattering” of different cohorts.66 However, survival data remain the gold 
standard, and availability of survival data has increased with the recently published 
CONCORD-2 study,4 which provides survival estimates for 67 countries.
Conclusions
Cancer was the second leading cause of death in 2013 after cardiovascular disease (eFigure 
5a in the Supplement), and cancer burden as part of the NCDs is expected to increase in all 
countries due to population growth, aging, and an increasing prevalence of certain risk 
factors.1 The health community has responded to this global health threat through endorsing 
the “25 by 25” strategy as part of the NCD Global Monitoring Framework during the World 
Health Assembly in 2012,67 with the goal of reducing avoidable mortality from NCDs by 
25% by 2025. This is a challenging goal and will require commitment from all levels of 
society. Population-level observations of cancer burden and time trends as presented herein 
help highlight aspects of cancer epidemiology that can guide intervention programs and 
advance research in cancer determinants and outcomes.
Cancer control strategies have to be prioritized based on local needs, and current data on 
cancer burden will be necessary for the development of national NCD action and cancer 
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control plans. In acknowledgment of this need, annual updates of the burden of cancer will 
be published.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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At a Glance
• In 2013, there were 14.9 million new cancer cases and 8.2 million cancer deaths.
• For women, breast cancer was the leading cause of disability-adjusted life years 
(DALYs) globally and in developed and developing countries.
• For men, lung cancer was the leading cause of DALYs globally and in 
developed and developing countries.
• For men, incident cases have increased the most for prostate cancer at the global 
setting and in developed and developing countries.
• For women at the global level, incident cases have increased the most for non-
Hodgkin lymphoma; in developed countries, incident cases have increased the 
most for kidney cancer; in developing countries, incident cases have increased 
the most for breast cancer.
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Figure 1. Age-Specific Global Contributions of Cancer Types to Total Cancer Incidence and 
Mortality, 2013
For International Classification of Diseases codes included in the other neoplasms group, 
see eTable 15 in the Supplement.
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Figure 2. Relative Changes in Age-Standardized Incidence and Death Rates in Both Sexes for All 
Cancers Except NMSC and KS in 188 Countries From 1990 to 2013
ATG indicates Antigua and Barbuda; BRB, Barbados; COM, Comoros; DMA, Dominica; E 
Med: Eastern Mediterranean; FJI, Fiji; FSM, Federated States of Micronesia; GRD, 
Grenada; KIR, Kiribati; KS, Kaposi sarcoma; LCA, Saint Lucia; MDV, Maldives; MLT, 
Malta; MUS, Mauritius; MHL, Marshall Islands; NMSC, nonmelanoma skin cancer; SGP, 
Singapore; SLB, Solomon Islands; SYC, Seychelles; TLS, Timor-Leste; TON, Tonga; TTO, 
Trinidad and Tobago; VCT, Saint Vincent and the Grenadines; VUT, Vanuatu; W Africa, 
West Africa; WSM, Samoa.
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Figure 3. Cancers Ranked by Number of Incident Cases in Both Sexes, Globally, by 
Development Status, and in the 50 Most Populous Countries, 2013
Colors correspond to the ranking, with dark red as the most common cancer and dark green 
as the least common cancer for the location indicated. Rankings do not include the “other 
cancer” group (eTable 15 in the Supplement). The numbers inside each box indicate the 
ranking.
a
 Developing country.
b
 Democratic Republic of Congo.
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Figure 4. Cancers Ranked by Number of Deaths in Both Sexes, Globally, by Development Status, 
and in the 50 Most Populous Countries, 2013
Colors correspond to the ranking, with dark red as the cancer with the most deaths and dark 
green as the cancer with the least deaths for the location indicated. Rankings do not include 
the “other cancer” group (eTable 15 in the Supplement). The numbers inside each box 
indicate the ranking.
a
 Developing country.
b
 Democratic Republic of Congo.
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Figure 5. Cancers Ranked Globally and for Both Sexes by Absolute Years of Life Lost (YLLs) 
Including the Percentage Change in Absolute YLLs and the Percentage Change in the Age-
Standardized YLL Rate Between 1990 and 2013
The “other cancers” group (eTable 15 in the Supplement) is not included here because it 
contains multiple different types of cancers. Solid lines connecting the 1990 and 2013 charts 
indicate increased or unchanged rank for the connected cancers; dotted lines indicated 
decreased rank.
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Figure 6. Trends in Age-Standardized Incidence Rates for Tracheal, Bronchus, and Lung 
Cancer, 1990-2013
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Figure 7. Trends in Age-Standardized Incidence Rates for Female Breast Cancer, 1990-2013
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Figure 8. Trends in Age-Standardized Incidence Rates for Colon and Rectum Cancer, 1990-2013
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Figure 9. Trends in Age-Standardized Incidence Rates for Prostate Cancer, 1990-2013
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Figure 10. Trends in Age-Standardized Incidence Rates for Stomach Cancer, 1990-2013
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Figure 11. Trends in Age-Standardized Incidence Rates for Liver Cancer, 1990-2013
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Figure 12. Trends in Age-Standardized Incidence Rates for Cervical Cancer, 1990-2013
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Figure 13. Trends in Age-Standardized Incidence Rates for Non-Hodgkin Lymphoma, 
1990-2013
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Figure 14. Trends in Age-Standardized Incidence Rates for Esophageal Cancer, 1990-2013
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Figure 15. Trends in Age-Standardized Incidence Rates for Leukemia, 1990-2013
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Table 2
Decomposition Analysis of Cancer Trends in Global Incidence, Both Sexes, 1990 to 2013
Cancera
Incident Cases, No.
Expected Incident Cases, 
2013, No. Change in Incident Cases, 1990 to 2013, %
1990 2013
Given 
Population 
Growth 
Alone
Given 
Population 
Growth and 
Aging
Due to 
Population 
Growthb
Due to 
Change in 
Age 
Structurec
Due to 
Change in 
Incidence 
Ratesd
All except NMSC and KS 8 510 588 14 942 583 11 486 507 14 515 059 35.0 35.6 5.0
Esophageal 303 510 441 767 409 640 530 592 35.0 39.9 −29.3
Stomach 800 136 984 206 1 079 922 1 401 995 35.0 40.3 −52.2
Liver 465 014 792 203 627 617 800 507 35.0 37.2 −1.8
Larynx 137 785 176 687 185 964 238 499 35.0 38.1 −44.9
Tracheal, bronchus and lung 1 113 162 1 798 179 1 502 405 1 937 791 35.0 39.1 −12.5
Breast 906 618 1 804 209 1 223 637 1 568 145 35.0 38.0 26.0
Cervical 447 344 485 297 603 768 747 821 35.0 32.2 −58.7
Uterine 216 793 353 117 292 599 375 986 35.0 38.5 −10.5
Prostate 454 412 1 442 460 613 308 801 983 35.0 41.5 140.9
Colon and rectum 818 440 1 572 590 1 104 626 1 443 985 35.0 41.5 15.7
Lip and oral cavity 238 789 409 360 322 287 413 567 35.0 38.2 −1.8
Nasopharynx 67 658 83 702 91 316 112 072 35.0 30.7 −41.9
Other pharynx 80 691 139 567 108 907 140 604 35.0 39.3 −1.3
Gallbladder and biliary tract 136 503 186 253 184 234 242 255 35.0 42.5 −41.0
Pancreatic 183 076 350 361 247 093 323 423 35.0 41.7 14.7
Malignant skin melanoma 151 601 272 481 204 612 254 748 35.0 33.1 11.7
Ovarian 137 417 226 204 185 467 234 642 35.0 35.8 −6.1
Testicular 37 982 59 279 51 263 56 101 35.0 12.7 8.4
Kidney 142 463 294 501 192 279 241 697 35.0 34.7 37.1
Bladder 263 307 401 174 355 378 466 220 35.0 42.1 −24.7
Brain and central nervous 
system
193 980 304 528 261 809 293 291 35.0 16.2 5.8
Thyroid 115 627 225 566 156 058 187 946 35.0 27.6 32.5
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Cancera
Incident Cases, No.
Expected Incident Cases, 
2013, No. Change in Incident Cases, 1990 to 2013, %
1990 2013
Given 
Population 
Growth 
Alone
Given 
Population 
Growth and 
Aging
Due to 
Population 
Growthb
Due to 
Change in 
Age 
Structurec
Due to 
Change in 
Incidence 
Ratesd
Mesothelioma 16 972 33 744 22 906 29 561 35.0 39.2 24.6
Hodgkin lymphoma 103 249 93 345 139 353 142 599 35.0 3.1 −47.7
Non-Hodgkin lymphoma 226 661 465 488 305 918 373 548 35.0 29.8 40.6
Multiple myeloma 62 738 116 947 84 676 110 140 35.0 40.6 10.8
Leukemia 297 404 414 443 401 398 437 862 35.0 12.3 −7.9
Other neoplasms 391 255 1 014 928 528 066 607 480 35.0 20.3 104.1
Abbreviations: GBD, Global Burden of Disease; ICD-9, International Classification of Diseases, Ninth Revision; ICD-10, International Statistical 
Classification of Diseases and Related Health Problems, Tenth Revision; KS, Kaposi sarcoma; NMSC, nonmelanoma skin cancer; YLDs, years 
lived with disability; YLLs, years of life lost.
aCancer groups are defined based on ICD codes and include all codes pertaining to neoplasms (ICD-9 140-239; ICD-10 C00-D49) except for 
NMSC and KS. eTable 3 in the Supplement details how the original ICD codes were mapped to the standardized GBD cause list.1
b
To estimate the effect of population growth we applied the population size of 2013 onto the rate, sex, and age structure of 1990. Since the global 
population grew by 35% between 1990 and 2013, and rates and age structure remained the same as in 1990, incidence due to all cancers increased 
by 35% in this counterfactual scenario.
c
To estimate the effect of aging on incident cases we applied the age structure of 2013 onto the rate, sex distribution, and population size of 1990. 
The change in incident cases reported herein shows the proportion of the change in incident cases between 1990 and 2013 that can be attributed to 
the changing age structure of the population.
d
To estimate the effect of changing incidence rates on the incident cases we applied the incidence rates for 1990 onto the population size and age 
structure of 2013. The change in incident cases reported herein shows the proportion of the change in incident cases between 1990 and 2013 that 
can be attributed to a change in incidence rates.
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